Loading
Protease and Inhibitor Mechanisms · Journal article
Nigerian Postgraduate Medical Journal · August 17, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a small, single-centre cross-sectional immunohistochemistry study demonstrating increased CD10 expression in colorectal adenocarcinomas compared to adenomas. The finding is descriptive and correlative, without mechanistic validation, clinical outcomes, or independent replication; it is hypothesis-generating rather than confirmatory and does not support clinical decision-making.
Cross-sectional immunohistochemistry study. 58 colorectal adenomas (16) and adenocarcinomas (58); majority over 50 years of age; rectosigmoid the most common tumour site. Setting and exact inclusion/exclusion criteria not stated.. Intervention: CD10 immunostaining and expression analysis. Compared with: Adenomas versus adenocarcinomas. n = 58. Published in Nigerian Postgraduate Medical Journal; country of conduct not explicitly stated..
Increasing CD10 expression from adenomas (16 cases) to adenocarcinomas (58 cases) Significant increase in CD10 expression in adenocarcinomas compared to adenomas Most common tumour site was rectosigmoid region
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This work does not provide sufficient evidence to guide clinical practice. CD10 expression remains a research marker; its role in prognosis, treatment selection, or as a therapeutic target is not established and would require prospective cohort studies and/or mechanistic validation.
A small, single-centre, cross-sectional immunohistochemistry study showing increased CD10 expression from adenomas to carcinomas; descriptive and correlative, without mechanistic validation or clinical outcome data.
As stated by the source record.
Quoted from the source exactly as published.
This work does not provide sufficient evidence to guide clinical practice. CD10 expression remains a research marker; its role in prognosis, treatment selection, or as a therapeutic target is not established and would require prospective cohort studies and/or mechanistic validation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Abstract Background: Colorectal cancer is the fourth leading cause of cancer-related mortality worldwide. It is more prevalent in developed countries but is increasingly affecting developing nations in Asia and Africa. CD10 is a cell surface zinc-dependent matrix metalloproteinase which may play a crucial role in tumour progression, invasion and metastasis. Aims: The present study was done to analyse the CD10 role and its expression in colorectal Cancer. Materials and Methods: This cross-sectional study includes 58 cases, including colorectal adenomas (16) and carcinomas (58) over the period of 1½ years. The staining pattern and intensity of CD10 immunostaining were correlated with clinicopathological features of the cases. Results: The maximum number of cases were over 50 years of age, and the most common site of tumour was the rectosigmoid region. Our study showed increasing expression of CD10 from adenomas to adenocarcinomas, suggesting its role in colorectal tumourigenesis. This study highlights a significant increase in CD10 expression in adenocarcinomas compared to adenomas, reinforcing its importance in malignant transformation. Conclusion: The study concludes that there is a significant association between CD10 expression and colorectal carcinogenesis. CD10 may play a role in colorectal tumour progression and could be a potential target for anti-cancer therapy, particularly in rectosigmoid cancers.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.